Ignite Creation Date:
2025-12-25 @ 4:04 AM
Ignite Modification Date:
2025-12-26 @ 2:59 AM
Study NCT ID:
NCT00203502
Status:
COMPLETED
Last Update Posted:
2016-05-11
First Post:
2005-09-12
Is NOT Gene Therapy:
False
Has Adverse Events:
True
Brief Title:
Primary Systemic Therapy in Operable/Locally Advanced Breast Cancer
Sponsor:
Organization:
Raw JSON
{'hasResults': True, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-12-24'}, 'conditionBrowseModule': {'meshes': [{'id': 'D001943', 'term': 'Breast Neoplasms'}], 'ancestors': [{'id': 'D009371', 'term': 'Neoplasms by Site'}, {'id': 'D009369', 'term': 'Neoplasms'}, {'id': 'D001941', 'term': 'Breast Diseases'}, {'id': 'D012871', 'term': 'Skin Diseases'}, {'id': 'D017437', 'term': 'Skin and Connective Tissue Diseases'}]}, 'interventionBrowseModule': {'meshes': [{'id': 'D000068258', 'term': 'Bevacizumab'}, {'id': 'D003520', 'term': 'Cyclophosphamide'}, {'id': 'D000077143', 'term': 'Docetaxel'}, {'id': 'D004317', 'term': 'Doxorubicin'}], 'ancestors': [{'id': 'D061067', 'term': 'Antibodies, Monoclonal, Humanized'}, {'id': 'D000911', 'term': 'Antibodies, Monoclonal'}, {'id': 'D000906', 'term': 'Antibodies'}, {'id': 'D007136', 'term': 'Immunoglobulins'}, {'id': 'D007162', 'term': 'Immunoproteins'}, {'id': 'D001798', 'term': 'Blood Proteins'}, {'id': 'D011506', 'term': 'Proteins'}, {'id': 'D000602', 'term': 'Amino Acids, Peptides, and Proteins'}, {'id': 'D012712', 'term': 'Serum Globulins'}, {'id': 'D005916', 'term': 'Globulins'}, {'id': 'D010752', 'term': 'Phosphoramide Mustards'}, {'id': 'D009588', 'term': 'Nitrogen Mustard Compounds'}, {'id': 'D009150', 'term': 'Mustard Compounds'}, {'id': 'D006846', 'term': 'Hydrocarbons, Halogenated'}, {'id': 'D006838', 'term': 'Hydrocarbons'}, {'id': 'D009930', 'term': 'Organic Chemicals'}, {'id': 'D063088', 'term': 'Phosphoramides'}, {'id': 'D009943', 'term': 'Organophosphorus Compounds'}, {'id': 'D043823', 'term': 'Taxoids'}, {'id': 'D043822', 'term': 'Cyclodecanes'}, {'id': 'D003516', 'term': 'Cycloparaffins'}, {'id': 'D006840', 'term': 'Hydrocarbons, Alicyclic'}, {'id': 'D006844', 'term': 'Hydrocarbons, Cyclic'}, {'id': 'D004224', 'term': 'Diterpenes'}, {'id': 'D013729', 'term': 'Terpenes'}, {'id': 'D003630', 'term': 'Daunorubicin'}, {'id': 'D018943', 'term': 'Anthracyclines'}, {'id': 'D009279', 'term': 'Naphthacenes'}, {'id': 'D011084', 'term': 'Polycyclic Aromatic Hydrocarbons'}, {'id': 'D006841', 'term': 'Hydrocarbons, Aromatic'}, {'id': 'D011083', 'term': 'Polycyclic Compounds'}, {'id': 'D000617', 'term': 'Aminoglycosides'}, {'id': 'D006027', 'term': 'Glycosides'}, {'id': 'D002241', 'term': 'Carbohydrates'}]}}, 'resultsSection': {'moreInfoModule': {'pointOfContact': {'email': 'MakhoulIssam@uams.edu', 'phone': '5016868274', 'title': 'Dr. Issam Makhoul', 'organization': 'University of Arkansas for Medical Sciences'}, 'certainAgreement': {'piSponsorEmployee': True}}, 'adverseEventsModule': {'description': 'If a subject experienced more than 1 of a given AE, the subject is only counted once for that AE. If a subject experienced more than one AE is a system organ class, the subject is only counted once in that system organ class.', 'eventGroups': [{'id': 'EG000', 'title': 'Intervention: Drug:Docetaxel + Cyclophosphamide + Avastin', 'description': 'Docetaxel 75mg/m2 + Cyclophosphamide 500 mg/m2\n\n\\+ Avastin 15 mg/kg\n\nQ 3 weeks X 4 cycles\n\nBevacizumab/Avastin: IV 15mg/kg 21 days\n\nCyclophosphamide: 500mg per meter squared, IV every 21 days\n\nDoxorubicin: 60 mg per meter squared, IV every 21 days', 'otherNumAtRisk': 39, 'otherNumAffected': 19, 'seriousNumAtRisk': 39, 'seriousNumAffected': 39}], 'otherEvents': [{'term': 'Alopecia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 39, 'numEvents': 19, 'numAffected': 19}], 'organSystem': 'Skin and subcutaneous tissue disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT'}, {'term': 'Constipation', 'stats': [{'groupId': 'EG000', 'numAtRisk': 39, 'numEvents': 19, 'numAffected': 19}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT'}, {'term': 'Fatigue', 'stats': [{'groupId': 'EG000', 'numAtRisk': 39, 'numEvents': 19, 'numAffected': 19}], 'organSystem': 'General disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT'}], 'seriousEvents': [{'term': 'infection', 'stats': [{'groupId': 'EG000', 'numAtRisk': 39, 'numEvents': 3, 'numAffected': 3}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT'}, {'term': 'pulmonary embolism', 'stats': [{'groupId': 'EG000', 'numAtRisk': 39, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'Respiratory, thoracic and mediastinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT'}, {'term': 'Musculoskeletal pain', 'stats': [{'groupId': 'EG000', 'numAtRisk': 39, 'numEvents': 10, 'numAffected': 6}], 'organSystem': 'Musculoskeletal and connective tissue disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT'}, {'term': 'Fatigue', 'stats': [{'groupId': 'EG000', 'numAtRisk': 39, 'numEvents': 8, 'numAffected': 4}], 'organSystem': 'General disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT'}, {'term': 'Diarrhea', 'stats': [{'groupId': 'EG000', 'numAtRisk': 39, 'numEvents': 4, 'numAffected': 3}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT'}, {'term': 'Nausea/vomiting', 'stats': [{'groupId': 'EG000', 'numAtRisk': 39, 'numEvents': 4, 'numAffected': 4}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT'}, {'term': 'Mucositis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 39, 'numEvents': 3, 'numAffected': 3}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT'}, {'term': 'Insomnia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 39, 'numEvents': 3, 'numAffected': 3}], 'organSystem': 'Psychiatric disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT'}, {'term': 'Hypertension', 'stats': [{'groupId': 'EG000', 'numAtRisk': 39, 'numEvents': 3, 'numAffected': 3}], 'organSystem': 'Vascular disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT'}, {'term': 'Urinary tract infection', 'stats': [{'groupId': 'EG000', 'numAtRisk': 39, 'numEvents': 2, 'numAffected': 2}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT'}, {'term': 'Anxiety', 'stats': [{'groupId': 'EG000', 'numAtRisk': 39, 'numEvents': 2, 'numAffected': 2}], 'organSystem': 'Psychiatric disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT'}, {'term': 'Depression', 'stats': [{'groupId': 'EG000', 'numAtRisk': 39, 'numEvents': 2, 'numAffected': 2}], 'organSystem': 'Psychiatric disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT'}, {'term': 'Syncope', 'stats': [{'groupId': 'EG000', 'numAtRisk': 39, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT'}, {'term': 'Febrile Neutropenia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 39, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'Blood and lymphatic system disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT'}, {'term': 'Heart failure', 'stats': [{'groupId': 'EG000', 'numAtRisk': 39, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'Cardiac disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT'}], 'frequencyThreshold': '5'}, 'outcomeMeasuresModule': {'outcomeMeasures': [{'type': 'PRIMARY', 'title': 'Percentage of Participants With Pathological Complete Response.', 'denoms': [{'units': 'Participants', 'counts': [{'value': '39', 'groupId': 'OG000'}]}], 'groups': [{'id': 'OG000', 'title': 'Intervention: Drug:Docetaxel + Cyclophosphamide + Avastin', 'description': 'Docetaxel 75mg/m2 + Cyclophosphamide 500 mg/m2\n\n\\+ Avastin 15 mg/kg\n\nQ 3 weeks X 4 cycles\n\nBevacizumab/Avastin: IV 15mg/kg 21 days\n\nCyclophosphamide: 500mg per meter squared, IV every 21 days\n\nDoxorubicin: 60 mg per meter squared, IV every 21 days'}], 'classes': [{'categories': [{'measurements': [{'value': '41', 'groupId': 'OG000', 'lowerLimit': '27.7', 'upperLimit': '55.4'}]}]}], 'paramType': 'NUMBER', 'timeFrame': 'Participants were assessed during surgery, an average of one hour', 'description': 'Pathological complete response was defined as the absence of residual invasive and in situ cancer on hematoxylin and eosin evaluation of the resected breast.', 'unitOfMeasure': 'percentage of evaluable patients', 'dispersionType': '90% Confidence Interval', 'reportingStatus': 'POSTED'}, {'type': 'SECONDARY', 'title': 'Number of Participants With Clinical Complete Response in Breast and the Axillary Lymph Nodes After the Completion of Chemotherapy and Bevacizumab.', 'denoms': [{'units': 'Participants', 'counts': [{'value': '38', 'groupId': 'OG000'}]}], 'groups': [{'id': 'OG000', 'title': 'Intervention: Drug:Docetaxel + Cyclophosphamide + Avastin', 'description': 'Docetaxel 75mg/m2 + Cyclophosphamide 500 mg/m2\n\n\\+ Avastin 15 mg/kg\n\nQ 3 weeks X 4 cycles\n\nBevacizumab/Avastin: IV 15mg/kg 21 days\n\nCyclophosphamide: 500mg per meter squared, IV every 21 days\n\nDoxorubicin: 60 mg per meter squared, IV every 21 days'}], 'classes': [{'categories': [{'measurements': [{'value': '53', 'groupId': 'OG000', 'lowerLimit': '39', 'upperLimit': '66'}]}]}], 'paramType': 'NUMBER', 'timeFrame': 'At completion of chemotherapy treatment, an average of one hour', 'description': 'Clinical complete response was defined using RECIST response categories as the clinical response to chemotherapy', 'unitOfMeasure': 'percentage of pts w/ cCR', 'dispersionType': '90% Confidence Interval', 'reportingStatus': 'POSTED', 'populationDescription': 'All participants evaluated surgically'}, {'type': 'SECONDARY', 'title': 'Percentage of Participants With Grade 3 or 4 Adverse Events', 'denoms': [{'units': 'Participants', 'counts': [{'value': '39', 'groupId': 'OG000'}]}], 'groups': [{'id': 'OG000', 'title': 'Intervention: Drug:Docetaxel + Cyclophosphamide + Avastin', 'description': 'Docetaxel 75mg/m2 + Cyclophosphamide 500 mg/m2\n\n\\+ Avastin 15 mg/kg\n\nQ 3 weeks X 4 cycles\n\nBevacizumab/Avastin: IV 15mg/kg 21 days\n\nCyclophosphamide: 500mg per meter squared, IV every 21 days\n\nDoxorubicin: 60 mg per meter squared, IV every 21 days'}], 'classes': [{'categories': [{'measurements': [{'value': '79', 'groupId': 'OG000', 'lowerLimit': '69', 'upperLimit': '90'}]}]}], 'paramType': 'NUMBER', 'timeFrame': 'After each chemotherapy infusion, approximately one hour', 'description': 'Percent of participants who had at least one grade 3 or 4 adverse event', 'unitOfMeasure': 'percentage of pts w/ grade 3/4 AE', 'dispersionType': '90% Confidence Interval', 'reportingStatus': 'POSTED'}, {'type': 'SECONDARY', 'title': 'To Measure the Change in Left Ventricular Ejection Fraction (LVEF) From Baseline', 'denoms': [{'units': 'Participants', 'counts': [{'value': '34', 'groupId': 'OG000'}]}], 'groups': [{'id': 'OG000', 'title': 'Intervention: Drug:Docetaxel + Cyclophosphamide + Avastin', 'description': 'Docetaxel 75mg/m2 + Cyclophosphamide 500 mg/m2\n\n\\+ Avastin 15 mg/kg\n\nQ 3 weeks X 4 cycles\n\nBevacizumab/Avastin: IV 15mg/kg 21 days\n\nCyclophosphamide: 500mg per meter squared, IV every 21 days\n\nDoxorubicin: 60 mg per meter squared, IV every 21 days'}], 'classes': [{'categories': [{'measurements': [{'value': '-3.5', 'spread': '7.0', 'groupId': 'OG000'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Immediately before treatment and 1 year after start of treatment', 'description': 'Absolute change in LVEF, where LVEF values are measured in percentage units', 'unitOfMeasure': 'Percentage of LVEF', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED'}, {'type': 'SECONDARY', 'title': 'Percentage of Participants With Pathologic Complete Response (pCR) Among Those With Triple Negative Breast Cancer', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'groups': [{'id': 'OG000', 'title': 'Intervention: Drug:Docetaxel + Cyclophosphamide + Avastin', 'description': 'Docetaxel 75mg/m2 + Cyclophosphamide 500 mg/m2\n\n\\+ Avastin 15 mg/kg\n\nQ 3 weeks X 4 cycles\n\nBevacizumab/Avastin: IV 15mg/kg 21 days\n\nCyclophosphamide: 500mg per meter squared, IV every 21 days\n\nDoxorubicin: 60 mg per meter squared, IV every 21 days'}], 'classes': [{'categories': [{'measurements': [{'value': '57', 'groupId': 'OG000', 'lowerLimit': '35', 'upperLimit': '79'}]}]}], 'paramType': 'NUMBER', 'timeFrame': 'at surgery, one day', 'description': 'pCR rate for triple negative patients--percent', 'unitOfMeasure': '% pCR among triple negative pts', 'dispersionType': '90% Confidence Interval', 'reportingStatus': 'POSTED', 'populationDescription': 'Patients with triple negative breast cancer'}]}, 'participantFlowModule': {'groups': [{'id': 'FG000', 'title': 'Intervention: Drug:Docetaxel + Cyclophosphamide + Avastin', 'description': 'Docetaxel 75mg/m2 + Cyclophosphamide 500 mg/m2\n\n\\+ Avastin 15 mg/kg\n\nQ 3 weeks X 4 cycles\n\nBevacizumab/Avastin: IV 15mg/kg 21 days\n\nCyclophosphamide: 500mg per meter squared, IV every 21 days\n\nDoxorubicin: 60 mg per meter squared, IV every 21 days'}], 'periods': [{'title': 'Overall Study', 'milestones': [{'type': 'STARTED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '40'}]}, {'type': 'COMPLETED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '39'}]}, {'type': 'NOT COMPLETED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '1'}]}], 'dropWithdraws': [{'type': 'Death', 'reasons': [{'groupId': 'FG000', 'numSubjects': '1'}]}]}], 'recruitmentDetails': 'This study recruited patients from September 9, 2005 through January 17, 2008. Patients were recruited from hematology/oncology clinic at the Winthrop P. Rockefeller Cancer Institute of the University of Arkansas for Medical Sciences.'}, 'baselineCharacteristicsModule': {'denoms': [{'units': 'Participants', 'counts': [{'value': '40', 'groupId': 'BG000'}]}], 'groups': [{'id': 'BG000', 'title': 'Intervention: Drug:Docetaxel + Cyclophosphamide + Avastin', 'description': 'Docetaxel 75mg/m2 + Cyclophosphamide 500 mg/m2\n\n\\+ Avastin 15 mg/kg\n\nQ 3 weeks X 4 cycles\n\nBevacizumab/Avastin: IV 15mg/kg 21 days\n\nCyclophosphamide: 500mg per meter squared, IV every 21 days\n\nDoxorubicin: 60 mg per meter squared, IV every 21 days'}], 'measures': [{'title': 'Age, Categorical', 'classes': [{'categories': [{'title': '<=18 years', 'measurements': [{'value': '0', 'groupId': 'BG000'}]}, {'title': 'Between 18 and 65 years', 'measurements': [{'value': '29', 'groupId': 'BG000'}]}, {'title': '>=65 years', 'measurements': [{'value': '11', 'groupId': 'BG000'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'unitOfMeasure': 'Participants'}, {'title': 'Age, Continuous', 'classes': [{'categories': [{'measurements': [{'value': '45', 'groupId': 'BG000', 'lowerLimit': '26', 'upperLimit': '72'}]}]}], 'paramType': 'MEDIAN', 'unitOfMeasure': 'years', 'dispersionType': 'FULL_RANGE'}, {'title': 'Sex: Female, Male', 'classes': [{'categories': [{'title': 'Female', 'measurements': [{'value': '40', 'groupId': 'BG000'}]}, {'title': 'Male', 'measurements': [{'value': '0', 'groupId': 'BG000'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'unitOfMeasure': 'Participants'}, {'title': 'Region of Enrollment', 'classes': [{'title': 'United States', 'categories': [{'measurements': [{'value': '40', 'groupId': 'BG000'}]}]}], 'paramType': 'NUMBER', 'unitOfMeasure': 'participants'}]}}, 'protocolSection': {'designModule': {'phases': ['PHASE2'], 'studyType': 'INTERVENTIONAL', 'designInfo': {'allocation': 'NA', 'maskingInfo': {'masking': 'NONE'}, 'primaryPurpose': 'TREATMENT', 'interventionModel': 'SINGLE_GROUP'}, 'enrollmentInfo': {'type': 'ACTUAL', 'count': 40}}, 'statusModule': {'overallStatus': 'COMPLETED', 'startDateStruct': {'date': '2005-09'}, 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2016-05', 'completionDateStruct': {'date': '2015-02', 'type': 'ACTUAL'}, 'lastUpdateSubmitDate': '2016-05-02', 'studyFirstSubmitDate': '2005-09-12', 'resultsFirstSubmitDate': '2015-10-21', 'studyFirstSubmitQcDate': '2005-09-12', 'lastUpdatePostDateStruct': {'date': '2016-05-11', 'type': 'ESTIMATED'}, 'resultsFirstSubmitQcDate': '2015-11-30', 'studyFirstPostDateStruct': {'date': '2005-09-20', 'type': 'ESTIMATED'}, 'resultsFirstPostDateStruct': {'date': '2016-01-05', 'type': 'ESTIMATED'}, 'primaryCompletionDateStruct': {'date': '2015-02', 'type': 'ACTUAL'}}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Percentage of Participants With Pathological Complete Response.', 'timeFrame': 'Participants were assessed during surgery, an average of one hour', 'description': 'Pathological complete response was defined as the absence of residual invasive and in situ cancer on hematoxylin and eosin evaluation of the resected breast.'}], 'secondaryOutcomes': [{'measure': 'Number of Participants With Clinical Complete Response in Breast and the Axillary Lymph Nodes After the Completion of Chemotherapy and Bevacizumab.', 'timeFrame': 'At completion of chemotherapy treatment, an average of one hour', 'description': 'Clinical complete response was defined using RECIST response categories as the clinical response to chemotherapy'}, {'measure': 'Percentage of Participants With Grade 3 or 4 Adverse Events', 'timeFrame': 'After each chemotherapy infusion, approximately one hour', 'description': 'Percent of participants who had at least one grade 3 or 4 adverse event'}, {'measure': 'To Measure the Change in Left Ventricular Ejection Fraction (LVEF) From Baseline', 'timeFrame': 'Immediately before treatment and 1 year after start of treatment', 'description': 'Absolute change in LVEF, where LVEF values are measured in percentage units'}, {'measure': 'Percentage of Participants With Pathologic Complete Response (pCR) Among Those With Triple Negative Breast Cancer', 'timeFrame': 'at surgery, one day', 'description': 'pCR rate for triple negative patients--percent'}]}, 'oversightModule': {'oversightHasDmc': False}, 'conditionsModule': {'keywords': ['Operable and Locally advanced Breast Cancer'], 'conditions': ['Breast Cancer']}, 'referencesModule': {'references': [{'pmid': '32298288', 'type': 'DERIVED', 'citation': 'Hsu PC, Kadlubar SA, Siegel ER, Rogers LJ, Todorova VK, Su LJ, Makhoul I. Genome-wide DNA methylation signatures to predict pathologic complete response from combined neoadjuvant chemotherapy with bevacizumab in breast cancer. PLoS One. 2020 Apr 16;15(4):e0230248. doi: 10.1371/journal.pone.0230248. eCollection 2020.'}, {'pmid': '28045923', 'type': 'DERIVED', 'citation': 'Makhoul I, Todorova VK, Siegel ER, Erickson SW, Dhakal I, Raj VR, Lee JY, Orloff MS, Griffin RJ, Henry-Tillman RS, Klimberg S, Hutchins LF, Kadlubar SA. Germline Genetic Variants in TEK, ANGPT1, ANGPT2, MMP9, FGF2 and VEGFA Are Associated with Pathologic Complete Response to Bevacizumab in Breast Cancer Patients. PLoS One. 2017 Jan 3;12(1):e0168550. doi: 10.1371/journal.pone.0168550. eCollection 2017.'}, {'pmid': '24577164', 'type': 'DERIVED', 'citation': 'Makhoul I, Griffin RJ, Siegel E, Lee J, Dhakal I, Raj V, Jamshidi-Parsian A, Klimberg S, Hutchins LF, Kadlubar S. High-circulating Tie2 Is Associated With Pathologic Complete Response to Chemotherapy and Antiangiogenic Therapy in Breast Cancer. Am J Clin Oncol. 2016 Jun;39(3):248-54. doi: 10.1097/COC.0000000000000046.'}, {'pmid': '23563210', 'type': 'DERIVED', 'citation': 'Makhoul I, Klimberg VS, Korourian S, Henry-Tillman RS, Siegel ER, Westbrook KC, Hutchins LF. Combined neoadjuvant chemotherapy with bevacizumab improves pathologic complete response in patients with hormone receptor negative operable or locally advanced breast cancer. Am J Clin Oncol. 2015 Feb;38(1):74-9. doi: 10.1097/COC.0b013e31828940c3.'}]}, 'descriptionModule': {'briefSummary': 'The main purpose of this study is to find out what effects taking the drug bevacizumab together with two chemotherapeutic agents, docetaxel and cyclophosphamide followed by doxorubicin alone before surgery will on breast cancer. Bevacizumab will be given for twelve weeks in combination with chemotherapy then it ill be held during the administration of doxorubicin. Twenty-eight to fifty-six days after undergoing surgery, all patients will receive nine three-weekly infusions of bevacizumab.', 'detailedDescription': 'Prior to being enrolled in this study, they will undergo an evaluation to determine eligibility. The study doctor will obtain a complete medical history, complete a physical examination including blood pressure and heart rate. The doctor will also obtain a baseline ECG as well as blood tests (approximately two tablespoons of blood). In order to decrease the effects of food, exercise and the sleep/wake cycle variability, all blood samples must be taken between 8AM - 10AM and patients will need to fast (no food or drink) for 10 hours prior to the blood test. Patients will also need to strain from working out prior to the blood test. The study will ask for a list of current medications. Patients will not be eligible if they have a history of or now require long-term anticoagulant (blood thinner) therapy (i.e. Coumadin or anything patients may be taking to prevent blood clots) have an allergy to bevacizumab or any other drugs used in the study.\n\nMany of the following evaluations are commonly done to determine diagnosis and/or stage of breast cancer and may have already had some of all of them done. If the following procedures were not done within three weeks, they will need to be done again prior to receiving any study therapy.\n\n* Diagnosis of breast cancer by fine needle aspiration or core needle biopsy will be required for entry in this study.\n* Clip Placement - a clip will be placed in the tumor during the core biopsies as a marker to assist surgeons at the time of surgery.\n* Tumor Clip Placements - a caliper is similar to a ruler and is used to measure the tumor from the outside of the body instead of always having to use an ultrasound or MRI.\n* Tumor Ultrasound - this is a non-invasive exam that uses sound waves to produce a picture of your tumor.\n\nAll study participants will be treated with bevacizumab 15 mg/kg plus docetaxel 75 mg/m2 and cyclophosphamide 500 mg/m2 every three weeks for a total of four treatments. Three weeks after the completion of this part of the treatment patients will start receiving doxorubicin 60 mg/m2 every three weeks for a total of four treatments. All these drugs will be given as intravenous infusion on the first day of each three-week period.\n\nPatients will come in for every three week visits and have a physical exam including blood pressure and heart rate. Medications lists will be taken and any side effects that may have been experienced. Tumor caliper measurements will be done and blood will be drawn at each of these visits.\n\nA mammogram and MUGA scan will be done again just prior to surgery. Patients will undergo tumor surgery approximately six months after treatment. Patients will need to visit the study physician one month after surgery for another physical examination including blood pressure and heart rate, an assessment of any side effects and a list of current medications.'}, 'eligibilityModule': {'sex': 'FEMALE', 'stdAges': ['ADULT', 'OLDER_ADULT'], 'minimumAge': '18 Years', 'healthyVolunteers': True, 'eligibilityCriteria': 'Inclusion Criteria:\n\n* The diagnosis of breast cancer established by biopsy.\n* Normal kidney function\n* Normal LVEF evaluated by MUGA Scan\n* \\>18 years of age\n* Good performance status defined by ECOG scale of 0 or 1\n* Consent\n* Women of childbearing potential must have a negative pregnancy test.\n* Use of effective means of contraception in subjects of child-bearing potential while on treatment and for at least 3 months thereafter.\n* Peripheral Neuropathy: must be \\< grade 1\n* Hematologic (minimal values)\n* Absolute neutrophil count \\>1,500/mm3\n* Hemoglobin \\>8.0 g/dl\n* Platelet count \\>100,000/mm3\n* Hepatic\n* Total bilirubin \\<ULN\n* AST, ALT, Alkaline Phosphatase must be within range\n\nExclusion Criteria:\n\n* Patients with locally advanced breast cancer with skin ulcerations\n* Stage IV breast cancer\n* Inflammatory breast cancer\n* Allergy to any component of the treatment regimen\n* Women who are breast feeding\n* Pregnancy or refusal to use effective contraception\n* Inability to comply with study and/or follow-up procedures.\n* Current, recent, or planned participation in a experimental drug study\n* Blood pressure of \\>150/100 mmHg. Essential hypertension well controlled with anti hypertensives is not an exclusion criterion.\n* unstable angina\n* New York Heart Association Grade II or greater congestive heart failure\n* history of myocardial infarction within 6 months\n* history of stroke within 6 months\n* Clinical significant peripheral vascular disease\n* Evidence of bleeding diathesis or coagulopathy\n* Presence of central nervous system or brain metastasis\n* major surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to day 0\n* Minor surgical procedure such as fine needle aspirations or core biopsy within 7 days prior to day 0\n* Pregnant or lactating\n* Urine protein: creatinine ratio \\>1.0 at screening\n* History of abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within 6 months prior to Day 0\n* Serious, non-healing wound, ulcer, or bone fracture'}, 'identificationModule': {'nctId': 'NCT00203502', 'briefTitle': 'Primary Systemic Therapy in Operable/Locally Advanced Breast Cancer', 'organization': {'class': 'OTHER', 'fullName': 'University of Arkansas'}, 'officialTitle': 'Primary Systemic Therapy Using Sequential Docetaxel/Cyclophosphamide/Bevacizumab Followed by Doxorubicin in Operable/Locally Advanced Breast Cancer', 'orgStudyIdInfo': {'id': 'UARK 2004-59'}}, 'armsInterventionsModule': {'armGroups': [{'type': 'EXPERIMENTAL', 'label': 'Intervention: Dtx Cyclophosphamide Bev', 'description': 'Docetaxel 75m/m2 Cyclophosphamide 500 mg/m2 Bevacizumab 15 mg/kg', 'interventionNames': ['Drug: Bevacizumab', 'Drug: Cyclophosphamide', 'Drug: Docetaxel']}], 'interventions': [{'name': 'Bevacizumab', 'type': 'DRUG', 'otherNames': ['Avastin'], 'description': 'IV 15mg/kg 21 days', 'armGroupLabels': ['Intervention: Dtx Cyclophosphamide Bev']}, {'name': 'Cyclophosphamide', 'type': 'DRUG', 'otherNames': ['Cytoxan'], 'description': '500mg per meter squared, IV every 21 days', 'armGroupLabels': ['Intervention: Dtx Cyclophosphamide Bev']}, {'name': 'Docetaxel', 'type': 'DRUG', 'otherNames': ['Taxotere', 'Adriamycin'], 'description': '60 mg per meter squared, IV every 21 days', 'armGroupLabels': ['Intervention: Dtx Cyclophosphamide Bev']}]}, 'contactsLocationsModule': {'locations': [{'zip': '72205', 'city': 'Little Rock', 'state': 'Arkansas', 'country': 'United States', 'facility': 'University of Arkansas for Medical Sciences', 'geoPoint': {'lat': 34.74648, 'lon': -92.28959}}], 'overallOfficials': [{'name': 'Issam Makhoul, MD', 'role': 'PRINCIPAL_INVESTIGATOR', 'affiliation': 'University of Arkansas'}]}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'University of Arkansas', 'class': 'OTHER'}, 'collaborators': [{'name': 'Genentech, Inc.', 'class': 'INDUSTRY'}], 'responsibleParty': {'type': 'SPONSOR'}}}}